Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06634589 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

A Phase 1 study of B-cell Lymphoma and Refractory Cancer, sponsored by BeOne Medicines.

Recruiting
Registry status
Phase 1
Development phase
80
Enrollment target
20
Study locations

NCT06634589: Recruiting Phase 1 study of B-cell Lymphoma and Refractory Cancer, sponsored by BeOne Medicines.

NCT06634589 is a Phase 1 study of B-cell Lymphoma and Refractory Cancer that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 80 participants, roughly in line with the 88-participant average among 38 other B-cell Lymphoma trials with a reported enrollment target. The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06634589, a Phase 1 study of B-cell Lymphoma and Refractory Cancer, is actively recruiting participants, sponsored by BeOne Medicines.

RECRUITING
Registry status
Phase 1
Development phase
80 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.

Conditions Studied

B-cell Lymphoma Refractory Cancer Relapsed Cancer B-cell Malignancy

Interventions

  • DRUG Zanubrutinib
  • DRUG BGB-16673
  • DRUG Sonrotoclax
  • DRUG Mosunetuzumab
  • DRUG Glofitamab

Study Locations (20)

New York

  • Icahn School of Medicine At Mount Sinai - New York
  • Columbia University Medical Center - New York
  • Weill Cornell Medical College Newyork Presbyterian Hospital - New York
  • Memorial Sloan Kettering Cancer Center Mskcc - New York
  • University of Rochester - Rochester

Florida

  • Mayo Clinic Jacksonville - Jacksonville
  • Moffitt Cancer Center - Tampa

Wisconsin

  • University of Wisconsin - Madison
  • Medical College of Wisconsin - Milwaukee

Arizona

  • Mayo Clinic Phoenix - Phoenix

California

  • University of Southern Californianorris Comprehensive - Los Angeles

Kansas

  • The University of Kansas Cancer Center - Westwood

Minnesota

  • Mayo Clinic Rochester - Rochester

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2024-11-27
Est. Completion 2029-12-02
Phase Phase 1
BeOne Medicines

29 total trials

What NCT06634589 shows while recruiting

NCT06634589 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, roughly in line with the 88-participant average among 38 other B-cell Lymphoma trials with a reported enrollment target.

The record links to 4 conditions, with B-cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Zanubrutinib is the first listed.

NCT06634589 names 20 study sites across 14 states, led by New York, Florida, Wisconsin.

Frequently Asked Questions

What is clinical trial NCT06634589 about?

NCT06634589 is a clinical study titled "A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies". The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separat...

What is the current status of trial NCT06634589?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2024-11-27. Estimated completion is 2029-12-02.

What conditions does trial NCT06634589 study?

This clinical trial studies the following conditions: B-cell Lymphoma, Refractory Cancer, Relapsed Cancer, B-cell Malignancy.

What interventions are being tested in trial NCT06634589?

The interventions under investigation include: Zanubrutinib (DRUG), BGB-16673 (DRUG), Sonrotoclax (DRUG), Mosunetuzumab (DRUG), Glofitamab (DRUG).

Who is sponsoring clinical trial NCT06634589?

This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06634589 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Kansas, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for B-cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06634589's enrollment target sits among peer trials

80 9th of 38 higher than 29 of 38 other B-cell Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other B-cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06634589

Source: ClinicalTrials.gov NCT06634589, the US trial registry maintained by the National Library of Medicine. NCT06634589 (small enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.